Preferentially Expressed Antigen in Melanoma (PRAME), a member of the cancer/testis
antigen family, is central to the field of skin cancer diagnostics and therapeutics. As a …

PRAME Immunohistochemistry as an Ancillary Test for the Assessment of Melanocytic
Lesions - Surgical Pathology Clinics Skip to Main Content Advertisement Surgical …

Preferentially expressed antigen in melanoma (PRAME) is considered a useful marker in the
differential diagnosis between malignant melanoma and its melanocytic mimics. Recently …

Background Programmed cell death receptor‐1 (PD‐1) monotherapy is a standard treatment
for advanced cutaneous melanoma, but its efficacy and toxicity are defined in white …

Abstract Background PReferentially expressed Antigen in MElanoma (PRAME)
immunohistochemical (IHC) staining is used to aid melanoma diagnosis. PRAME …

Abstract Background PRAME (PReferentially expressed Antigen in Melanoma)
immunohistochemistry has demonstrated high specificity for unequivocal melanomas; …

Increasing evidence shows that numerous cancer-testis antigens (CTAs) are uniquely
overexpressed in various types of cancer and most CTAs are oncogenic. Overexpression of …

PRAME (PReferentially expressed Antigen in MElanoma), a cancer-testis antigen expressed
in normal and neoplastic tissues with several functions, proved to be a useful diagnostic tool …

Background Immunohistochemistry‐based protein biomarkers can provide useful prognostic
information in cutaneous melanoma. The independent prognostic value of Ki‐67 has been …

Background Subungual melanoma can be diagnostically challenging. We evaluated the
potential of PReferentially expressed Antigen for MElanoma (PRAME) immunoreactivity for …